Maxinovel Pharmaceuticals Announces the Presentation of Its Orally Active PD-1/PD-L1 Inhibitors in 2018 AACR

GUANGZHOU, China--()--Maxinovel Pharmaceuticals today announces that it will present preclinical results of its orally active PD-1/PD-L1 inhibitors as a single agent or combination with Epacadostat, Celebrex, Cisplatin and CTLA-4, respectively. The presentation will be held in 2018 AACR in Chicago, USA. The details are as follows:

Title: Novel small molecule inhibitors of PD-1/PD-L1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel and Canonical Targets

Session Date and Time: Tuesday April 17, 2018 8:00am-12:00pm

Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 17

Permanent Abstract Number: 3851

About Maxinovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info:


Maxinovel Pharmaceuticals
Ms. Pingjing Zhang

Recent Stories

RSS feed for Maxinovel Pharmaceuticals, Inc.